Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced it will present at the Baird 2017 Global Healthcare Conference in New York, NY on Wednesday, September 6 at 10:50 a.m. ET.

A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170831005275/en/

IR or PR Contact:
Seres Therapeutics,
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
[email protected]

Source: Seres Therapeutics, Inc.

You May Also Be Interested In

• Baird Medical posts 25% revenue gain and slim profit in H1 2026
• Samsara Crosses $2.1 Billion in ARR as Large Enterprises Standardize on Its Platform
• IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster